Novo Nordisk: A long acting, selective human insulin analog, NN1213, for weight management Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Cagrilintide Research Peptide Information Peptpedia Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN